Join us for an insightful episode of the Oncology Brothers podcast as we dive deep into the world of renal cell carcinoma (RCC) with Dr. Katy Beckermann, the Medical GU Director of Cancer Research at Tennessee Oncology.

In this episode, hosts Drs. Rahul & Rohit Gosain, practicing medical oncologists, discuss the latest advancements in RCC treatment, including:
•⁠ ⁠The role of Pembrolizumab in the adjuvant setting based on the Keynote 564 study and its implications for early-stage disease.
•⁠ ⁠Current treatment paradigms for metastatic RCC, including dual checkpoint inhibitors, TKI with immunotherapy, and single-agent options.
•⁠ ⁠The importance of patient characteristics and IMDC risk categorization in treatment decisions.
•⁠ ⁠Insights into sequencing therapies, including the use of Belzutifan for refractory disease and the management of side effects.
•⁠ ⁠The role of ctDNA, PD-L1 testing, and NGS in RCC.

Whether you're a community oncologist or simply interested in the latest in cancer care, this episode is packed with valuable information to help you stay informed and provide the best care for your patients.

YouTube: https://youtu.be/Bbv9N7-YKIM

Follow us on social media:
•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠ Website: https://oncbrothers.com/

Don't forget to like, subscribe, and leave a review to let us know how we're doing and how we can continue to support you in the community!

The youth court is leading the way for neurodiverse people

Nine To Noon

Screening tools and identifying neurodiversity early

The AI-powered Podcast Player